First Horizon Advisors Inc. Decreases Stake in Edwards Lifesciences Corporation $EW

First Horizon Advisors Inc. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 14.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 8,488 shares of the medical research company’s stock after selling 1,403 shares during the quarter. First Horizon Advisors Inc.’s holdings in Edwards Lifesciences were worth $664,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in EW. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the first quarter valued at about $26,000. NewSquare Capital LLC raised its stake in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the last quarter. SouthState Corp purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $27,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $29,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Canaccord Genuity Group reaffirmed a “hold” rating and set a $84.00 price target (up previously from $81.00) on shares of Edwards Lifesciences in a research report on Monday. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a report on Monday. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $82.42 on Friday. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $87.09. The firm has a market capitalization of $48.39 billion, a P/E ratio of 11.86, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $77.74 and a two-hundred day simple moving average of $77.21.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.